Tonix reports Q1 net loss $14.9M; cash at $7.0M; advancing Tonmya NDA

Tonix Pharmaceuticals Holding Corp.

2024-Q1 EPS reported -$0.18 revenue$2,482,000

Net product revenue $2.5M from Zembrace/Tosymra; net loss $(14.9)M ($0.18/share) vs $(33.0)M ($3.21) YoY.
Cash $7.0M at Mar 31, 2024, down from $24.9M Dec 31; net cash used in ops $17.6M.
On track to submit NDA for Tonmya in H2 2024; pre-NDA FDA meeting scheduled Q2 2024.
Raised $4.4M in registered direct offering on Apr 1, 2024 (post-quarter).
R&D expenses down to $12.9M from $26.5M; G&A up to $9.3M from $7.4M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tonix Pharmaceuticals Holding Corp. reported financial results for first quarter ended March 31, 2024.

Period: first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 13, 2024, Tonix Pharmaceuticals Holding Corp. (the “Company”) announced its operating results for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Tonix Pharmaceuticals Holding Corp. filing history →

Source: SEC EDGAR

accession 0001999371-24-005990

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.